Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: An open-label, phase I study Journal Article
| Authors: | Paz-Ares, L.; Champiat, S.; Lai, W. V.; Izumi, H.; Govindan, R.; Boyer, M.; Hummel, H. D.; Borghaei, H.; Johnson, M. L.; Steeghs, N.; Blackhall, F.; Dowlati, A.; Reguart, N.; Yoshida, T.; He, K.; Gadgeel, S. M.; Felip, E.; Zhang, Y.; Pati, A.; Minocha, M. |
| Article Title: | Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: An open-label, phase I study |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 41 |
| Issue: | 16 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2023-06-01 |
| Start Page: | 2893 |
| End Page: | 2903 |
| Language: | English |
| DOI: | 10.1200/jco.22.02823 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| PUBMED: | 36689692 |
| PMCID: | PMC10414718 |
| DOI/URL: | |
| Notes: | Accession Number: 163946171 -- Entry Date: In Process -- Revision Date: 20230530 -- Publication Type: Article -- Journal Subset: Biomedical; Editorial Board Reviewed; Expert Peer Reviewed; Peer Reviewed; USA -- NLM UID: 8309333. -- Source: Cinahl |
